Scientists at the University of Calgary have made a discovery that could lead to treatment of Fragile X syndrome (FXS), the leading genetic cause of autism. The study, involving mouse models, shows promise of translating to a treatment for people. Those with FXS are missing a protein vital to brain development called FMRP. The researchers used a fragment of FMRP which was able to cross the blood-brain barrier and restore the protein to normal levels.
- Addition of sintilimab to pemetrexed and platinum improved progression-free survival
- Phase 3 eXalt3 study shows significantly longer progression-free survival
- checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab
- Scientists discover curious clues in the war between cf bacteria
- Predicting drought in the American West just got more difficult